HCT-15-luc Orthotopic Mouse Model Service for Colon Cancer

The HCT-15-luc orthotopic mouse model integrates the KRAS^G13D-driven, microsatellite-instability-high molecular signature of human colorectal adenocarcinoma with constitutive firefly luciferase expression, enabling sensitive, non-invasive, longitudinal quantification of tumor burden, therapeutic response, and metastatic dissemination within the native cecal wall microenvironment. Alfa Cytology engineers this advanced bioluminescent xenograft system with authenticated HCT-15-Luc2 cell banks, precision cecal wall surgical implantation, and calibrated IVIS imaging protocols, delivering real-time tumor kinetics data and comprehensive molecular endpoint analysis to accelerate your KRAS-directed and MSI-H-focused colon cancer drug discovery program.

Overview of HCT-15-luc Orthotopic Mouse Model for Colon Cancer

The HCT-15-luc cell line is a genetically engineered derivative of the parental HCT-15 human colorectal adenocarcinoma line, stably transduced with a lentiviral vector encoding the firefly luciferase 2 (luc2) reporter gene and subsequently isolated through single-cell cloning to ensure homogeneous, constitutive expression. The parental HCT-15 line was established from a Dukes type C primary tumor classified within the prestigious NCI-60 cancer cell line panel, carrying a heterozygous KRAS^G13D oncogenic driver, biallelic PIK3CA activating mutations (p.Glu545Lys and p.Asp549Asn), heterozygous TP53 inactivation, and microsatellite instability-high (MSI-H) status—a molecular constellation that distinguishes it from microsatellite-stable counterparts and aligns it with the immune-activated consensus molecular subtype. The luciferase reporter integration yields a signal-to-noise ratio exceeding 1,000 and a bioluminescent output of at least 100,000 photons per cell per second under standard imaging conditions, enabling quantitative detection of as few as several hundred cells in vitro and real-time tumor burden assessment in vivo without interim animal sacrifice.

Fig 1. Longitudinal luciferase imaging of an HCT15 orthotopic colorectal cancer mouse model established by cecal inoculation, enabling non-invasive monitoring of primary tumor burden and therapeutic response in vivo. (Lin, Yanyun, et al., 2025)

When established as an orthotopic xenograft within the cecal wall of immunodeficient mice, HCT-15-luc recapitulates the serosal-submucosal invasion dynamics and mesenteric lymphatic drainage patterns characteristic of human colorectal carcinoma. Implantation into the cecal mesenteric triangle—where the colonic wall lacks serosal covering and portal venous vasculature converges—facilitates physiologic angiogenesis, regional lymph node involvement, and hematogenous metastasis to the liver. Unlike conventional subcutaneous models that rely on caliper-based tumor volume estimation, the HCT-15-luc orthotopic platform leverages bioluminescence imaging to capture tumor establishment as early as 3–5 days post-implantation, monitor exponential growth phase with photon flux quantification, detect therapeutic response within 24–72 hours of drug administration, and distinguish true tumor regression from pseudoresponse or stromal edema. This optical precision, combined with the MSI-H molecular context and KRAS/PI3K pathway dysregulation, renders the model uniquely suited for evaluating combination regimens, nanoparticle delivery systems, and DNA damage response modulators in a preclinical framework where quantitative longitudinal readouts directly inform translational decision-making.

Cell Line Information: HCT-15-luc

HCT-15-luc is a luciferase-reporter derivative of the NCI-60 panel human colorectal adenocarcinoma HCT-15 cell line, engineered for constitutive firefly luciferase 2 expression and validated for quantitative bioluminescence imaging applications. The following table summarizes its biological origin, genetic architecture, reporter characteristics, and culture specifications:

Our Services

Alfa Cytology delivers comprehensive HCT-15-luc orthotopic model services spanning authenticated luciferase-stable NCI-60 panel cell bank maintenance, cecal wall surgical implantation with validated direct injection or tumor fragment grafting techniques, serial bioluminescence imaging on calibrated IVIS platforms, and terminal multimodal endpoint analysis. Our capabilities include KRAS^G13D allele-specific validation, PI3K pathway biomarker assessment, mismatch repair deficiency characterization, and MSI-H phenotyping alongside quantitative optical tracking. We support single-agent efficacy studies, combination matrices with dose-escalation arms, nanoparticle delivery evaluations, and pharmacokinetic bridging investigations, all executed under AAALAC-accredited animal care standards with rigorous data documentation and GLP-compliant reporting upon request.

Workflow of HCT-15-luc Orthotopic Mouse Model Construction

Construction of the HCT-15-luc orthotopic model integrates reporter cell line quality assurance, sterile surgical technique, and standardized bioluminescence imaging calibration to ensure reproducible engraftment and quantitative tumor tracking. Our protocol is optimized for consistent optical signal fidelity, minimal perioperative mortality, and robust therapeutic readouts suitable for KRAS-directed and MSI-H-focused therapeutic assessment. The workflow proceeds as follows:

1. Master Cell Bank Revival and Reporter Validation: HCT-15-luc master stocks are revived and expanded in antibiotic-free RPMI 1640 medium. Each production lot undergoes STR profiling against the ATCC reference database, mycoplasma PCR screening, KRAS^G13D allele-specific qPCR validation, and in vitro luciferase functional assay (Bright-Glo or equivalent) to confirm reporter expression levels, signal linearity across 10^2–10^6 cells, and signal-to-noise ratio >= 1,000 prior to surgical use.
2. Pre-Implantation Cell or Tumor Fragment Preparation: Two validated engraftment routes are prepared. Route A (direct cell injection): logarithmic-phase HCT-15-luc cells are harvested with 0.05% trypsin-EDTA, washed twice in sterile PBS, and resuspended at 1–2 x 10⁷ cells/mL in ice-cold PBS or PBS/Matrigel (1:1 v/v) for a 30 μL cecal wall inoculum. Route B (tumor fragment grafting): subcutaneous donor tumors are grown in nude mice, excised at ~100–150 mm³, necrotic tissue is trimmed, and fragments are sectioned to 0.15 mg pieces with weight verified on a precision microbalance (±0.05 mg deviation).
3. Recipient Mouse Preparation and Anesthesia: Female athymic nude mice (BALB/c nu/nu, 6–8 weeks, 18–22 g) are acclimated for 7 days under SPF barrier conditions. On the procedure day, general anesthesia is induced with 1–2% isoflurane in medical oxygen via nose cone. The ventral abdomen is shaved, cleansed sequentially with povidone-iodine and 70% ethanol, and draped sterilely.
4. Cecal Mesenteric Triangle Orthotopic Implantation: A 3–5 mm lower midline laparotomy exposes the cecum. For Route A, a 30-gauge Hamilton micro-syringe delivers 1 x 10⁶ cells in 30 μL PBS/Matrigel into the subserosal muscularis of the cecal mesenteric triangle, where the colonic wall lacks serosal covering and vascular ingress facilitates engraftment. For Route B, a 0.15 mg tumor fragment is positioned on the cecal serosa and secured with 8-0 absorbable sutures or a biocompatible tissue adhesive (~10 μL, drying 10–15 s). The cecum is returned to the peritoneal cavity, and the abdominal wall and skin are closed with 5-0 absorbable sutures or surgical staples.
5. Post-Operative Recovery and Clinical Surveillance: Mice recover on a heated pad until fully ambulatory. Post-operative analgesia (buprenorphine 0.05–0.1 mg/kg, s.c.) is administered per IACUC guidelines. Daily monitoring for 7–10 days assesses wound integrity, body weight, food intake, and abdominal distension. Humane endpoints include >20% body weight loss, wound dehiscence, or signs of severe distress.
6. Baseline Bioluminescence Imaging and Cohort Enrollment: Starting 3–5 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS Spectrum system. Baseline total flux (photons/sec) is recorded for each animal. Mice with confirmed bioluminescent signal are enrolled; those without detectable engraftment are excluded. Cohorts are randomized once mean tumor burden reaches a predefined threshold (e.g., 1–5 x 10⁶ photons/sec).
7. Therapeutic Intervention and Longitudinal Bioluminescence Monitoring: Test articles are administered per protocol via oral gavage, intravenous, intraperitoneal, or subcutaneous routes. Tumor burden is monitored via bioluminescence imaging twice weekly; body weights and clinical observations are recorded three times weekly. Blood samples may be collected for pharmacokinetic analysis, CEA biomarker quantification, or circulating tumor DNA assessment. The optical readout enables early detection of treatment response, typically within 24–72 hours for cytotoxic or targeted agents, and distinguishes true regression from pseudoresponse.
8. Necropsy, Tumor Harvest, and Multimodal Endpoint Analysis: At study termination, mice are humanely euthanized. The primary cecal tumor is excised, weighed, photographed, and dimensions recorded. Ex vivo bioluminescence of excised tumors and organs is captured to corroborate in-life imaging data. The abdominal cavity is inspected for peritoneal carcinomatosis. Metastatic target organs (liver, lung, spleen, mesenteric lymph nodes) are harvested. Tissues are fixed in 10% neutral buffered formalin for H&E histology, or snap-frozen for molecular analysis. Immunohistochemistry for Ki-67, cleaved caspase-3, CD31, KRASG13D, phospho-ERK1/2, phospho-AKT, and MLH1/MSH2 provides mechanistic insight into proliferation, apoptosis, angiogenesis, MAPK/PI3K pathway suppression, and mismatch repair status.

Fig 2. HCT-15-luc Orthotopic Mouse Model construction workflow.

Case Study-HCT-15-luc Orthotopic Mouse Model Development

In a recent preclinical program, the HCT-15-luc orthotopic model was utilized to evaluate the therapeutic efficacy of a liposomal irinotecan nanoformulation in combination with a selective ATR inhibitor against KRAS^G13D-driven, MSI-H colorectal cancer. HCT-15-luc cells were implanted into the cecal wall of athymic nude mice via subserosal injection, with tumor engraftment confirmed by bioluminescence imaging within 3–5 days. Mice were randomized at a mean photon flux of approximately 2 x 10⁶ photons/sec and dosed for 3 weeks. The combination arm demonstrated progressive bioluminescent signal attenuation beginning at day 5 of treatment, whereas vehicle and monotherapy groups exhibited continued exponential photon flux increase. At necropsy, the combination cohort showed significantly reduced primary cecal tumor weight and diminished ex vivo bioluminescence of excised tumors compared to controls. Notably, immunohistochemical analysis revealed increased γH2AX staining—indicative of DNA damage accumulation—and reduced phospho-ERK1/2 intensity in the combination group, suggesting that ATR inhibition sensitizes KRAS-mutant, MSI-H tumors to topoisomerase I poisoning by exacerbating replication stress. These findings illustrate how the HCT-15-luc orthotopic platform integrates real-time optical tracking with mechanistic biomarker analysis to deconvolute combination therapy activity in a single in vivo experiment.

Why Choose Alfa Cytology?

Preclinical programs targeting KRAS-mutant, MSI-high colorectal cancer demand a model that combines molecular driver fidelity, anatomical relevance, and quantitative longitudinal readouts. Alfa Cytology structures its HCT-15-luc orthotopic service around these imperatives, delivering capabilities that distinguish our offering in the preclinical CRO landscape:

• We maintain authenticated, low-passage HCT-15-luc master and working cell banks with documented STR profiles, routine mycoplasma surveillance, KRAS^G13D allele-specific qPCR validation, and serial luciferase activity QC—ensuring reporter fidelity and genetic stability across every study batch.
• Our surgical team achieves consistent engraftment via both direct cecal wall injection and tumor fragment grafting techniques, with bioluminescence signal detectable within 3–5 days and minimal perioperative mortality under AAALAC-accredited animal care standards.
• Bioluminescence imaging is conducted on calibrated IVIS Spectrum platforms with standardized D-luciferin dosing, exposure parameters, and automated ROI analysis protocols, yielding photon flux data with inter-study reproducibility suitable for cross-study meta-analysis.
• The optical reporter enables objective, non-invasive cohort randomization based on quantified tumor burden rather than subjective palpation, eliminating enrollment bias and improving statistical power—particularly critical for combination studies where early response differentiation is essential.
• We offer integrated multimodal endpoint analysis as standard, including ex vivo bioluminescence corroboration, digital whole-slide H&E pathology, IHC for MAPK and PI3K pathway biomarkers (phospho-ERK1/2, phospho-AKT), mismatch repair protein assessment (MLH1, MSH2, MSH6, PMS2), and DNA damage response markers (γH2AX, RAD51).
• Study designs are fully modular—we accommodate nanoparticle delivery assessments, complex combination matrices with dose-escalation arms, and pharmacokinetic bridging studies, with GLP-compliant documentation available to support IND-enabling packages and regulatory submissions.

Contact Us

If your colorectal cancer research program targets the KRAS-mutant, MSI-high population and requires an orthotopic model with real-time bioluminescent tracking, quantitative longitudinal monitoring, and deep molecular endpoint characterization, we invite you to reach out to us for a confidential project consultation. The scientific team at Alfa Cytology is prepared to design a customized HCT-15-luc orthotopic study aligned with your therapeutic hypothesis, compound formulation, and regulatory milestones. Contact us today to receive a detailed proposal, feasibility assessment, and projected timeline—let us advance your KRAS-directed pipeline with rigorous, publication-quality preclinical data.

For research use only. Not intended for any clinical use.